Emergence of depressive symptoms in patients receiving alprazolam for panic disorder.
The authors relate their clinical experience with 46 panic disorder patients who were receiving 3-10 mg/day of alprazolam. Fifteen (33%) developed symptoms consistent with DSM-III criteria for major depression despite remission of their panic symptoms. Clinicians should be alert to this potentially reversible complication.
D000328:Adult; D000525:Alprazolam / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D003866:Depressive Disorder / Q000139:chemically induced* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005239:Fear; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D010200:Panic
D007099:Imipramine; D000525:Alprazolam